Junghee J Shin1, Daniel Liauw1, Sabrina Siddiqui1, Juhyeon Lee1, Eun Jae Chung1, Ryan Steele1, Florence Ida Hsu1, Christina Price1, Insoo Kang2. 1. Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar Street, New Haven, CT, 06520, USA. 2. Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar Street, New Haven, CT, 06520, USA. Insoo.kang@yale.edu.
Abstract
PURPOSE: Although common variable immunodeficiency (CVID) is considered the most prevalent symptomatic primary antibody deficiency (PAD), there is a population with symptomatic PADs that do not meet criteria for CVID. We analyzed clinical and immunological profiles of patients with different PADs to better understand the differences and similarities between CVID and other PADs. METHODS: We extracted clinical and laboratory data of patients with PADs from electronic medical records. Patients were categorized into CVID, IgG subclass 2 deficiency (IgG2D), IgG deficiency (IgGD), and specific antibody deficiency (sAbD) based on basal immunoglobulin levels and pneumococcal vaccine responses. We compared clinical and immunological characteristics in these groups. RESULTS: All patients, regardless of PAD types, showed similar frequencies of infections, bronchiectasis, and interstitial lung disease (ILD). Hematopoietic malignancies were more frequently found in the CVID than in the IgG2D, IgGD, and sAbD groups, while the latter groups trended towards an increased frequency of connective tissue diseases (CTD). Low counts of natural killer (NK) cells were associated with malignancy, autoimmunity, and ILD in CVID but not in other PAD groups. CONCLUSIONS: Higher frequency of hematopoietic malignancy in CVID than in the other PADs and association of lower NK cell counts with non-infectious complications in CVID suggest a relationship between immune alterations and the development of non-infectious manifestations in PADs.
PURPOSE: Although common variable immunodeficiency (CVID) is considered the most prevalent symptomatic primary antibody deficiency (PAD), there is a population with symptomatic PADs that do not meet criteria for CVID. We analyzed clinical and immunological profiles of patients with different PADs to better understand the differences and similarities between CVID and other PADs. METHODS: We extracted clinical and laboratory data of patients with PADs from electronic medical records. Patients were categorized into CVID, IgG subclass 2 deficiency (IgG2D), IgG deficiency (IgGD), and specific antibody deficiency (sAbD) based on basal immunoglobulin levels and pneumococcal vaccine responses. We compared clinical and immunological characteristics in these groups. RESULTS: All patients, regardless of PAD types, showed similar frequencies of infections, bronchiectasis, and interstitial lung disease (ILD). Hematopoietic malignancies were more frequently found in the CVID than in the IgG2D, IgGD, and sAbD groups, while the latter groups trended towards an increased frequency of connective tissue diseases (CTD). Low counts of natural killer (NK) cells were associated with malignancy, autoimmunity, and ILD in CVID but not in other PAD groups. CONCLUSIONS: Higher frequency of hematopoietic malignancy in CVID than in the other PADs and association of lower NK cell counts with non-infectious complications in CVID suggest a relationship between immune alterations and the development of non-infectious manifestations in PADs.
Entities:
Keywords:
Common variable immunodeficiency; IgG deficiency; IgG subclass 2 deficiency; Primary antibody deficiency; Selective IgG subclass deficiency; Specific antibody deficiency
Authors: Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz Journal: J Allergy Clin Immunol Pract Date: 2015-11-07
Authors: Jordan S Orange; Mark Ballow; E Richard Stiehm; Zuhair K Ballas; Javier Chinen; Maite De La Morena; Dinakantha Kumararatne; Terry O Harville; Paul Hesterberg; Majed Koleilat; Sean McGhee; Elena E Perez; Jason Raasch; Rebecca Scherzer; Harry Schroeder; Christine Seroogy; Aarnoud Huissoon; Ricardo U Sorensen; Rohit Katial Journal: J Allergy Clin Immunol Date: 2012-09 Impact factor: 10.793
Authors: Elena Blanco; Martín Pérez-Andrés; Sonia Arriba-Méndez; Cristina Serrano; Ignacio Criado; Lucía Del Pino-Molina; Susana Silva; Ignacio Madruga; Marina Bakardjieva; Catarina Martins; Ana Serra-Caetano; Alfonso Romero; Teresa Contreras-Sanfeliciano; Carolien Bonroy; Francisco Sala; Alejandro Martín; José María Bastida; Félix Lorente; Carlos Prieto; Ignacio Dávila; Miguel Marcos; Tomas Kalina; Marcela Vlkova; Zita Chovancova; Ana Isabel Cordeiro; Jan Philippé; Filomeen Haerynck; Eduardo López-Granados; Ana E Sousa; Mirjam van der Burg; Jacques J M van Dongen; Alberto Orfao Journal: J Allergy Clin Immunol Date: 2019-02-28 Impact factor: 10.793
Authors: Claudia Wehr; Teemu Kivioja; Christian Schmitt; Berne Ferry; Torsten Witte; Efrem Eren; Marcela Vlkova; Manuel Hernandez; Drahomira Detkova; Philip R Bos; Gonke Poerksen; Horst von Bernuth; Ulrich Baumann; Sigune Goldacker; Sylvia Gutenberger; Michael Schlesier; Florence Bergeron-van der Cruyssen; Magali Le Garff; Patrice Debré; Roland Jacobs; John Jones; Elizabeth Bateman; Jiri Litzman; P Martin van Hagen; Alessandro Plebani; Reinhold E Schmidt; Vojtech Thon; Isabella Quinti; Teresa Espanol; A David Webster; Helen Chapel; Mauno Vihinen; Eric Oksenhendler; Hans Hartmut Peter; Klaus Warnatz Journal: Blood Date: 2007-09-26 Impact factor: 22.113
Authors: P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel Journal: Clin Exp Immunol Date: 2007-06-12 Impact factor: 4.330
Authors: V A Oxelius; A B Laurell; B Lindquist; H Golebiowska; U Axelsson; J Björkander; L A Hanson Journal: N Engl J Med Date: 1981-06-11 Impact factor: 91.245
Authors: Nely Rodriguez-Zhurbenko; Tam D Quach; Thomas J Hopkins; Thomas L Rothstein; Ana M Hernandez Journal: Front Immunol Date: 2019-03-19 Impact factor: 7.561
Authors: Ivan Angulo; Oscar Vadas; Fabien Garçon; Edward Banham-Hall; Vincent Plagnol; Timothy R Leahy; Helen Baxendale; Tanya Coulter; James Curtis; Changxin Wu; Katherine Blake-Palmer; Olga Perisic; Deborah Smyth; Mailis Maes; Christine Fiddler; Jatinder Juss; Deirdre Cilliers; Gašper Markelj; Anita Chandra; George Farmer; Anna Kielkowska; Jonathan Clark; Sven Kracker; Marianne Debré; Capucine Picard; Isabelle Pellier; Nada Jabado; James A Morris; Gabriela Barcenas-Morales; Alain Fischer; Len Stephens; Phillip Hawkins; Jeffrey C Barrett; Mario Abinun; Menna Clatworthy; Anne Durandy; Rainer Doffinger; Edwin R Chilvers; Andrew J Cant; Dinakantha Kumararatne; Klaus Okkenhaug; Roger L Williams; Alison Condliffe; Sergey Nejentsev Journal: Science Date: 2013-10-17 Impact factor: 47.728
Authors: Joo Hee Kim; Jae Hyuk Jang; So Hee Lee; Eun Mi Yang; Seung Hun Jang; Ki Suck Jung; Hae Sim Park Journal: Allergy Asthma Immunol Res Date: 2021-03 Impact factor: 5.764
Authors: John K Kuster; Serhan Unlu; Thomas A Makin; Jennefer Par-Young; Michael Simonov; Shamsa Shafi; Matthew Balanda; Christopher Randolph; Ryan Steele; Florence Ida Hsu; Christina Price; Anita Kohli-Pamnani; Larry Borish; Monica G Lawrence; Insoo Kang; Junghee J Shin Journal: J Allergy Clin Immunol Pract Date: 2021-12-18
Authors: Kai M T Sauerwein; Christoph B Geier; Roman F Stemberger; Hüseyin Akyaman; Peter Illes; Michael B Fischer; Martha M Eibl; Jolan E Walter; Hermann M Wolf Journal: Front Immunol Date: 2022-02-14 Impact factor: 7.561